Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clopidogrel intravenous - Ligand Pharmaceuticals

Drug Profile

Clopidogrel intravenous - Ligand Pharmaceuticals

Alternative Names: Captisol-Enabled® clopidogrel; Clopidogrel intravenous - CyDex; MDCO-157; PM 103; sulfobutylether β-cyclodextrin-enabled clopidogrel

Latest Information Update: 23 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CyDex Pharmaceuticals; Prism Pharmaceuticals
  • Developer Ligand Pharmaceuticals
  • Class 2 ring heterocyclic compounds; Antiplatelets; Chlorobenzenes; Esters; Pyridines; Small molecules; Thienopyridines
  • Mechanism of Action Platelet ADP receptor antagonists; Platelet aggregation inhibitors; Purinergic P2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Coronary thrombosis

Most Recent Events

  • 30 Jun 2013 The Medicines Company and Ligand Pharmaceuticals terminate their licensing agreement for intravenous clopidogrel
  • 31 Jan 2013 The Medicines Company completes a phase I trial in healthy volunteers in France (NCT01860105)
  • 30 Sep 2012 The Medicines Company initiates enrolment in a phase I bioequivalence trial for Coronary thrombosis prevention
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top